

[illegible][illegible]

Fig. 1

Fig. 1

Fig. 2

2/2

2/2 RetroGram 1.4

New Patient

Patient ID: abc 123

Print

Save

Help

6

7

8

Patient Details

Laboratory Information

HIV Therapy Decision Support

6

7

8

Legend

A

B

C

D

EU

Double click a drug name to view the available references supporting its ranking.

Interpret Substitutions

PIs		NRTIs		NNRTIs	
Current Treatment	New Treatment	Current Treatment	New Treatment	Current Treatment	New Treatment
amprenavir	<input type="radio"/>	abacavir	<input type="radio"/>	delavirdine	<input type="radio"/>
amprenavir/rtv	<input type="radio"/>	didanosine	<input type="radio"/>	efavirenz	<input type="radio"/>
saquinavir	<input type="radio"/>	lamivudine	<input type="radio"/>	nevirapine	<input type="radio"/>
saquinavir/rtv	<input type="radio"/>	zalcitabine	<input type="radio"/>		
indinavir/rtv	<input type="radio"/>	stavudine	<input type="radio"/>		
lopinavir/rtv	<input type="radio"/>	zidovudine	<input type="radio"/>		
nelfinavir	<input type="radio"/>				
indinavir	<input type="radio"/>				
ritonavir	<input type="radio"/>				

Lopinavir is co-formulated with ritonavir.
Nelfinavir: no data on boosting is available.

Fig. 3

Literature references supporting this ranking for zidovudine :

Mayers DL, Japour AJ, Arduino JM, Hammer SM, Reichman R, Wagner KF, Chung R, Lane J, Crumpacker CS, McLeod GX, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob. Agents Chemother. 1994; 38:307-314.

Hooker DJ, Tachedjian G, Solomon AE, Gursinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-2'-deoxythymidine. J Virol 1996; 70:8010-8018.

Jellinger, R. M., R. W. Shafer, and T. C. Merigan. 1997. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. J. Infect. Dis. 175:3,561-566.

Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A 1992; 89:1934-1938.

OK

Fig. 4